In an effort to develop a firmer understanding of the genomic landscape that characterizes the development and progression of squamous cell lung cancer, investigators conducted a detailed qualitative ...

The FDA is currently reviewing Summit's PD-1/VEGF bispecific as part of a chemotherapy combo for the treatment of locally advanced or metastatic non-squamous non-small cell lung cancer.

Squamous cell carcinoma of the lung is linked to smoking and requires early detection and accurate staging for effective treatment. Diagnosis involves imaging and biopsy, with the TNM system used to ...

A recent study has analyzed the relationship between different air pollutants and the main subtypes of lung cancer.

Invasive lung squamous cell carcinoma (LUSC) accounts for approximately one-quarter of all lung cancers, but therapeutic options for LUSC remain limited, primarily due to the absence of well-defined, ...

CHAF1B, a histone chaperone component of the chromatin assembly factor-1 complex, is overexpressed in multiple cancers and linked to tumor progression, but its role in lung squamous-cell carcinoma ...

Candel Therapeutics has identified a subpopulation of lung cancer patients living longest on its oncolytic virus, leading the biotech to narrow its focus as it heads towards a potentially ...

BioNTech's gotistobart receives FDA orphan drug designation, showing promise in improving survival for patients with squamous non–small cell lung cancer.